This episode delivers comprehensive insights into EU regulatory developments across electronic product information (ePI), bone complication treatments, Urssaf employment obligations, and monetary policy under the European Central Bank (ECB).

The European Union is advancing its ePI initiative with a phased roadmap starting late 2026, initially focusing on vaccines and oncology products before expanding to all centrally authorized medicines by 2028. This transition requires applicants to integrate ePI documents into the product lifecycle management portal alongside traditional submissions.

In the pharmaceutical sector, updated guidance on Xgeva (denosumab) emphasizes adherence to dosing schedules and patient supplementation with calcium and vitamin D to mitigate risks such as osteonecrosis of the jaw.

On the labor front, Urssaf has communicated critical data to assist companies in fulfilling their DOETH declarations related to the employment of disabled workers, with compliance deadlines and reporting requirements clearly outlined.

Monetary policy remains cautious as the ECB maintains interest rates amid inflationary pressures and geopolitical uncertainties. The ECB advises financial institutions to monitor evolving risks and highlights tools like the Transmission Protection Instrument to safeguard market stability.

For more information, visit the Carver Agents website.

Articles mentioned:

1. DOETH : notification des effectifs par l'Urssaf
2. Schriftliche Information zur 98. Routinesitzung nach § 63 AMG am 19. März 2026
3. Innovation Fund 2025 auctions attract almost €10 billion of bids from European industry for decarbonisation support
4. Commission launches call for evidence on targeted revision of EU water legislation
5. Electronic product information (ePI) roadmap
6. 2026-03-16 - 反倾销 - 欧盟对涉华铜管发起反倾销调查
7. Geldpolitische Beschlüsse vom 19. März 2026
8. 19/03/2026 - Medicine: Xgeva - denosumab
9. Geldpolitische Beschlüsse vom 19. März 2026 (Full Document)
10. Sanctions Notice - Russia